Clinical Trials

Adverum Biotechnologies, Inc , a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced the dosing of the first patient in the ADVANCE Phase 1/2 clinical trial of ADVM-043 for alpha-1 antitrypsin (A1AT)...

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type 1 diabetes (T1D), announced the completion of the final visit of the last patient included...

Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting rare, serious chronic inflammatory and fibrotic diseases, announced that it has initiated the Company's Phase 3 study ("RESOLVE-1") to test the efficacy and safety of anabasum in...

Eisai Co .Ltd. announced that a presentation on the updated analysis of a global Phase Ib/II clinical study (ENHANCE 1 / Study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product...

Plasticell, a developer of innovative stem cell technologies and cell therapies announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex...

Inovio Pharmaceuticals, Inc announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success. VGX-3100, Inovio’s lead product now in a pivotal phase...

OSE Immunotherapeutics announces that the Independent Data Monitoring Committee (IDMC) has recommended to the trial’s steering committee that accrual of the Tedopi® Phase 3 trial for the treatment of advanced non-small cell lung cancer (NSCLC) could resume with a...